Is MRI/US-guided fusion biopsy ready to replace systematic biopsy in detecting clinically significant prostate carcinoma? - a retrospective study

MRI/US引导融合活检能否取代系统性活检用于检测具有临床意义的前列腺癌?——一项回顾性研究

阅读:1

Abstract

BACKGROUND: This study aims to evaluate whether MRI-US-guided FB leads to improved diagnostic accuracy compared to SB and whether SB remains necessary for the detection of csPCa, further assessing whether the TP or TR biopsy approach influences outcomes. METHODS: In this retrospective single-center study, 851patients with PI-RADS ≥ 3 lesions on mpMRI underwent combined FB and SB between June 2019 and November 2024. The highest ISUP Grade Group per patient was compared between methods. Discordant findings were analyzed, and csPCa detection rates were compared between TP and TR approaches. RESULTS: FB detected higher ISUP-GG values in 70.9% of discordant cases. csPCa (ISUP-GG 2–5) was identified in 42.2% of patients with FB compared to 28.5% with SB (p < 0.001), while rates of ciPCa were similar. FB missed PCa (ISUP-GG 1–5) in 6.5% of patients. TP biopsy demonstrated higher csPCa detection than TR biopsy (50.1% vs. 43.0%, p = 0.038). CONCLUSION: FB significantly improves detection of csPCa compared to SB. However, FB cannot yet replace SB as it would miss total PCa in 6.5% of patients, thus the use of both methods together provides the most reliable diagnosis. Further TP approach provides higher csPCa detection and should be preferred when feasible. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12894-026-02113-5.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。